Evidence map›Paper›PMID 38567527›Full record

ArticleCirculation. Heart failure2024

mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice.

Wei Wu, Qi Jin, Cecilia Östlund, Kurenai Tanji, Ji-Yeon Shin, Jiying Han, Cheng-Shiun Leu, Jared Kushner, Howard J Worman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. RRAGD p.(Ser76Leu) Variant Causes Dysregulated Expression of Muscle Development and Cytoskeleton Genes in Cardiomyocytes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei WuDepartment of Medicine, Vagelos College of Physicians and Surgeons, (W.W., Q.J., C.Ö., J.-Y.S., J.K., H.J.W.), Columbia University, New York, NY.
Qi JinDepartment of Medicine, Vagelos College of Physicians and Surgeons, (W.W., Q.J., C.Ö., J.-Y.S., J.K., H.J.W.), Columbia University, New York, NY.ORCID 0009-0006-1483-6142
Cecilia ÖstlundDepartment of Medicine, Vagelos College of Physicians and Surgeons, (W.W., Q.J., C.Ö., J.-Y.S., J.K., H.J.W.), Columbia University, New York, NY.
Kurenai TanjiDepartment of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons (W.W., Q.J., C.Ö., K.T., H.J.W.), Columbia University, New York, NY.ORCID 0000-0003-2230-2416
Ji-Yeon ShinDepartment of Medicine, Vagelos College of Physicians and Surgeons, (W.W., Q.J., C.Ö., J.-Y.S., J.K., H.J.W.), Columbia University, New York, NY.ORCID 0000-0003-0598-1576
Jiying HanDepartment of Biostatistics, Mailman School of Public Health (J.H., C.-S.L.), Columbia University, New York, NY.
Cheng-Shiun LeuDepartment of Biostatistics, Mailman School of Public Health (J.H., C.-S.L.), Columbia University, New York, NY.ORCID 0000-0002-0301-8316
Jared Kushner *Department of Medicine, Vagelos College of Physicians and Surgeons, (W.W., Q.J., C.Ö., J.-Y.S., J.K., H.J.W.), Columbia University, New York, NY.ORCID 0000-0003-4821-0990
Howard J Worman *Department of Medicine, Vagelos College of Physicians and Surgeons, (W.W., Q.J., C.Ö., J.-Y.S., J.K., H.J.W.), Columbia University, New York, NY.

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Pathogenesis of Emery-Dreifuss Muscular DystrophyR01AR048997 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WORMAN, HOWARD J · 2003 to 2024
$7.1M
Regulators and interactomes of CaV1.2 in health and diseaseK08HL151969 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KUSHNER, JARED S · 2021 to 2025
$827k
NCATS NIH HHS UL1 TR001873NHLBI NIH HHS K08 HL151969NIAMS NIH HHS R01 AR048997
6 · The paper itself

Abstract

backgroundMutations in

methodsWe treated male

resultsEverolimus treatment (n=17) significantly reduced left ventricular dilatation and increased contractility on echocardiography, with a 7% (

conclusionsThese results suggest that mTOR inhibitors may be beneficial in patients with cardiomyopathy caused by

Indexed as

CardiomyopathiesDrug-Related Side Effects and Adverse ReactionsHeart FailureAnimalsEverolimusHumansLamin Type AMaleMammalsMechanistic Target of Rapamycin Complex 1MiceMTOR InhibitorsMutationTOR Serine-Threonine KinasesEverolimusLamin Type AMechanistic Target of Rapamycin Complex 1MTOR InhibitorsTOR Serine-Threonine Kinasescardiomyopathieseverolimuslaminsmicenuclear envelope

Identifiers

PMID38567527
PMCPMC11008450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.